GUERBET (EPA:GBT) Guerbet 2009 Net Sales

Transparency directive : regulatory news

11/02/2010 08:41

PRESS RELEASE

                             2009 Net Sales

Villepinte, 11 February 2010

Consolidated Group revenue (IFRS)

In thousands of euros          2009       2008     Change
First quarter                79,031     75,573      +4.6%
Second quarter               83,485     81,376      +2.6%
Third quarter                81,997     79,160      +3.6%
Fourth quarter               83,485     81,376      +2.6%
   TOTAL                    335,479    320,783      +4.6%

Consolidated revenue by region

In thousands of euros       2009       2008     Change
European subsidiaries    259,193    251,912      +2.9%
Other markets             76,286     68,872     +10.8%
  TOTAL                  335,479    320,783      +4.6%

Robust revenue growth in the fourth quarter (+7.2%)

Dotarem, Guerbet's flagship product in magnetic resonance imaging (MRI)
delivered another good performance. In line with trends over the full year,
Dotarem maintained its growth momentum in the fourth quarter in all markets
where it is sold, particularly in France and Germany.

For the full year and worldwide, Dotarem's sales grew 9.5% (+17.2% in volume).

In the x-ray imaging segment, Xenetix sales accelerated in the year's final
quarter, driven by growth in "Other markets" consisting notably of Brazil, China
and other Asian countries.

In this region and for the full year, Xenetix sales expanded 22.8% while in
Europe remained largely stable.

For all regions combined, Xenetix sales grew 4.9% in 2009 (+21.6% in volume).

Overall, Guerbet's consolidated revenue in 2009 grew 4.6%, sustained by further
market share gains, the addition of new accounts and expanded geographical
coverage for the Group's products in a highly competitive environment.

Efforts to strengthen R&D were accompanied by increased expenditures. These
included the launch of clinical phases of the programme for Dotarem's filing in
the US and the continued development of new chemical entities.

The combined effect of these developments and industrial production cost trends
will contribute to lower current operating income compared to 2008 while the net
margin is expected to marginally exceed 6%.

The capital spending programme has continued with the progressive commissioning
of new facilities in France in Lanester, Marans and Gonesse. These investments
were pursued adversely affecting debt that remained stable in relation to 31
December 2008

A complete presentation of Group results for fiscal 2009 with comments will be
published on 2 March 2010.

Contact: Finance Department. Tel: +33 (0)1 45 91 50 11

GUERBET's latest news

20/03/2024 18:00

GUERBET (EPA:GBT) Guerbet 2009 Net Sales

Transparency directive : regulatory news

GUERBET's latest news

Other stories